Stillwater Capital Advisors LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 0.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 378,646 shares of the biopharmaceutical company’s stock after selling 1,804 shares during the period. Pfizer comprises 3.2% of Stillwater Capital Advisors LLC’s holdings, making the stock its 7th biggest position. Stillwater Capital Advisors LLC’s holdings in Pfizer were worth $13,714,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Investment Centers of America Inc. lifted its position in Pfizer by 2.3% during the third quarter. Investment Centers of America Inc. now owns 195,611 shares of the biopharmaceutical company’s stock valued at $6,990,000 after acquiring an additional 4,472 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH lifted its position in Pfizer by 437.9% during the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 773,073 shares of the biopharmaceutical company’s stock valued at $27,607,000 after acquiring an additional 629,361 shares during the last quarter. Stanley Laman Group Ltd. lifted its position in Pfizer by 373.7% during the second quarter. Stanley Laman Group Ltd. now owns 114,284 shares of the biopharmaceutical company’s stock valued at $3,839,000 after acquiring an additional 90,160 shares during the last quarter. Atlantic Trust LLC lifted its position in Pfizer by 19.8% during the second quarter. Atlantic Trust LLC now owns 27,400 shares of the biopharmaceutical company’s stock valued at $748,000 after acquiring an additional 4,530 shares during the last quarter. Finally, ProVise Management Group LLC lifted its position in Pfizer by 5.9% during the second quarter. ProVise Management Group LLC now owns 244,076 shares of the biopharmaceutical company’s stock valued at $8,198,000 after acquiring an additional 13,616 shares during the last quarter. 70.43% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts recently commented on PFE shares. SunTrust Banks reissued a “hold” rating and set a $40.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Monday, January 29th. Jefferies Group set a $39.00 target price on shares of Pfizer and gave the company a “hold” rating in a research report on Monday, February 26th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.98 target price for the company. in a research report on Monday, January 15th. Bank of America set a $40.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. Finally, BMO Capital Markets set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, February 5th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $39.40.
Pfizer Inc. (NYSE:PFE) opened at $36.77 on Monday. The stock has a market cap of $218,890.00, a price-to-earnings ratio of 21.01, a price-to-earnings-growth ratio of 2.07 and a beta of 0.91. Pfizer Inc. has a fifty-two week low of $31.67 and a fifty-two week high of $39.43. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The business’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the company posted $0.47 earnings per share. sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd were issued a $0.34 dividend. The ex-dividend date of this dividend was Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.70%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is currently 77.71%.
Pfizer announced that its board has authorized a share buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.
COPYRIGHT VIOLATION NOTICE: “Pfizer Inc. (PFE) is Stillwater Capital Advisors LLC’s 7th Largest Position” was originally reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.themarketsdaily.com/2018/03/12/pfizer-inc-pfe-is-stillwater-capital-advisors-llcs-7th-largest-position.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.